In breast cancer, though the ER expression on the tumor often correlates with the clinical decision around hormonal therapies, the expression level of ER in vivo is variable and the definition of the expression level of the ER should comply with the latest ASCO (the American Society of Clinical Oncology)/CAP (the College of American Pathologists) guidance [61]. The gene discussed is ESR1; the disease is breast carcinoma.